Transactions
February 2 2026
TripleTree advises par8o, an R1 RCM company, on its acquisition by NuvemRx
NuvemRx, a leading tech-enabled pharmacy service for community health providers, announced it has acquired the 340B referral capture business formerly known as par8o from R1 RCM. par8o is an innovative healthcare technology company specializing in 340B referral capture with expansive integrations across large pharmacy partners, including Walgreens and CVS. The acquisition expands NuvemRx’s ability to help covered entities more effectively capture specialty referrals, retain patients within their networks, comply with ongoing rebate and reimbursement changes, and grow eligible prescription savings under the 340B Drug Pricing Program.
LEAD INVESTMENT BANKERS
Seth Kneller
Carmine Cafasso
NuvemRx, a leading tech-enabled pharmacy service for community health providers, announced it has acquired the 340B referral capture business formerly known as par8o from R1 RCM. par8o is an innovative healthcare technology company specializing in 340B referral capture with expansive integrations across large pharmacy partners, including Walgreens and CVS. The acquisition expands NuvemRx’s ability to help covered entities more effectively capture specialty referrals, retain patients within their networks, comply with ongoing rebate and reimbursement changes, and grow eligible prescription savings under the 340B Drug Pricing Program.
LEAD INVESTMENT BANKERS
Seth Kneller
Carmine Cafasso
We prioritize your privacy. We do not sell your information and will only send occasional, relevant emails.
Copyright © 2025 TripleTree, LLC.
All Rights Reserved